Looks like you need to subcribe to get to it ... seems free .... not sure ....
Research Reports Initiated on Healthcare Stocks Acerus Pharma, Mettrum Health, Aurinia Pharma, and Lattice Biologics
On Tuesday, August 30, 2016, The Toronto Exchange Composite Index closed at 14,684.85, slightly up 0.02% on trading volume of 311,127,368 shares. The TSX Venture Composite Index, on the other hand, dropped 1.93% ending the day at 790.35 on a total volume of 171,696,310 shares traded during the session.
Active Wall St. has initiated research reports on the following equities: Acerus Pharmaceuticals Corporation (TSX: ASP), Mettrum Health Corporation (TSX-V: MT), Aurinia Pharmaceuticals Inc. (TSX: AUP), and Lattice Biologics Ltd. (TSX-V: LBL). Register with us now for your free membership and research reports at: https://www.activewallst.com/register/.
Acerus Pharmaceuticals Corporation (TSX: ASP)
On Tuesday, shares in Mississauga, Canada headquartered Acerus Pharmaceuticals Corp. ended the session 8.57% higher at $0.19 with a total volume of 612,300 shares traded. Acerus Pharmaceuticals' shares have rallied 90.00% in the last one month and 35.71% in the previous three months. The stock is trading above its 50-day and 200-day moving averages. The company's 200-day moving average of $0.14 is greater than its 50-day moving average of $0.12. Shares of Acerus Pharmaceuticals, which focuses on developing, manufacturing, marketing, and distributing pharmaceutical products for male hypogonadism, women's hormone replacement therapy, and female sexual dysfunction in Canada, are trading at a PE ratio of 7.60. See our research report on ASP.TO at: https://www.activewallst.com/registration-3/?symbol=ASP.
Mettrum Health Corp. (TSX-V: MT)
Bowmanville, Canada headquartered Mettrum Health Corp.'s stock finished Tuesday's session 0.38% higher at $2.63 with a total volume of 329,069 shares traded. Over the past three months and the previous one year, shares of Mettrum Health, which engages in the research, development, production, and distribution of medical cannabis and cannabis products in Canada, have rallied 58.43% and 94.81%, respectively. However, the Company's stock has fallen by 4.36% in the last one month. The Company's shares are trading above its 200-day moving average. Mettrum Health's 50-day moving average of $2.63 is above its 200-day moving average of $1.92. The complimentary research report on MT.V at: https://www.activewallst.com/registration-3/?symbol=MT.
Aurinia Pharmaceuticals Inc. (TSX: AUP)
Victoria, Canada headquartered clinical stage pharmaceutical company, Aurinia Pharmaceuticals Inc.'s stock advanced 2.40%, to close the day at $2.56. The stock recorded a trading volume of 13,236 shares. Shares of Aurinia Pharmaceuticals, which engages in the development of a therapeutic drug to treat autoimmune diseases in Canada, are trading below their 50-day and 200-day moving averages. Moreover, the stock's 50-day moving average of $3.83 is greater than its 200-day moving average of $3.59. Register for free and access the latest research report on AUP.TO at: https://www.activewallst.com/registration-3/?symbol=AUP.
Lattice Biologics Ltd. (TSX-V: LBL)
On Tuesday, shares in Scottsdale, Arizona headquartered Lattice Biologics Ltd. recorded a trading volume of 48,000 shares, which was higher than their three months average volume of 37,681 shares. The stock ended the day 4.00% lower at $0.24. Shares of Lattice Biologics, which provides personalized/precision medicine for cellular therapies and tissue engineering, have gained 9.09% in the last one month and 26.32% in the previous three months. The Company is trading above its 50-day and 200-day moving averages at $0.22. Get free access to your research report on LBL.V at: https://www.activewallst.com/registration-3/?symbol=LBL.
Active Wall Street:
Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
AWS has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://www.activewallst.com/disclaimer/.